Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: A systematic review

Calcified Tissue International

Volumn 87, Issue 6, 2010, Pages 469-484

  Gallacher, S J ^b   Dixon, T ^a  

^a JB Medical Ltd   (United Kingdom)

^b NONE

Author keywords

Bisphosphonate; Bone quality; Denosumab; Osteoporosis; Strontium ranelate; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLLAGEN TYPE 1; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE MASS; BONE MATRIX; BONE MINERALIZATION; BONE STRUCTURE; BONE TURNOVER; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STRESS FRACTURE; SYSTEMATIC REVIEW; TRABECULAR BONE;

AGED; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RANK LIGAND; TERIPARATIDE; THIOPHENES;

EID: 78649326406     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9420-x     Document Type: Review

References (86)

1. PD Delmas E Seeman 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy Bone 34 599 604 1:CAS:528:DC%2BD2cXisF2ntL4%3D 10.1016/j.bone.2003.12. 022 15050889 (Pubitemid 38393794)
2. ES Siris YT Chen TA Abbott E Barrett-Connor PD Miller LE Wehren, et al. 2004 Bone mineral density thresholds for pharmacological intervention to prevent fractures Arch Intern Med 164 1108 1112 10.1001/archinte.164.10.1108 15159268 (Pubitemid 38668990)
3. P Chen PD Miller R Recker H Resch A Rana I Pavo, et al. 2007 Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis J Bone Miner Res 22 1173 1180 1:CAS:528:DC%2BD2sXptlGlsr4%3D 10.1359/jbmr.070413 17451369 (Pubitemid 351339699)
4. JJ Stepan DB Burr I Pavo A Sipos D Michalska J Li, et al. 2007 Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis Bone 41 378 385 10.1016/j.bone.2007.04. 198 17597017 (Pubitemid 47199146)
5. EB Kwek SK Goh JS Koh MA Png TS Howe 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39 224 231 10.1016/j.injury.2007.08.036 18222447
6. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301 1:CAS:528:DC%2BD2MXisVOhsr0%3D 10.1210/jc.2004-0952 15598694 (Pubitemid 40463979)
7. M Visekruna D Wilson FE McKiernan 2008 Severely suppressed bone turnover and atypical skeletal fragility J Clin Endocrinol Metab 93 2948 2952 1:CAS:528:DC%2BD1cXpvVOmurg%3D 10.1210/jc.2007-2803 18522980
8. AA Khan GK Sándor E Dore AD Morrison M Alsahli F Amin Canadian Taskforce on Osteonecrosis of the Jaw, et al. 2009 Bisphosphonate associated osteonecrosis of the jaw J Rheumatol 36 478 490 10.3899/jrheum.080759 19286860
9. A Khan 2010 Osteonecrosis of the jaw and bisphosphonates BMJ 340 c246 10.1136/bmj.c246 20124367
10. S Khosla D Burr J Cauley DW Dempster PR Ebeling D Felsenberg American Society for Bone and Mineral Research, et al. 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 1479 1491 10.1359/jbmr.0707onj 17663640 (Pubitemid 351229318)
11. P Szulc E Seeman 2009 Thinking inside and outside the envelopes of bone: dedicated to PDD Osteoporos Int 20 1281 1288 1:STN:280:DC%2BD1Mvns1CrsQ%3D%3D 10.1007/s00198-009-0994-y 19590836
12. JE Compston 2007 Skeletal actions of intermittent parathyroid hormone: effects on bone remodeling and structure Bone 40 1447 1452 1:CAS:528: DC%2BD2sXlsF2ntLc%3D 10.1016/j.bone.2006.09.008 17045858 (Pubitemid 46756408)
13. AA Reszka GA Rodan 2003 Bisphosphonate mechanism of action Curr Rheumatol Rep 5 65 74 10.1007/s11926-003-0085-6 12590887
14. JP Brown RL Prince C Deal RR Recker DP Kiel LH de Gregorio, et al. 2009 Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 153 161 1:CAS:528:DC%2BD1MXht1yrtbc%3D 10.1359/jbmr.0809010 18767928
15. PJ Marie 2006 Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation Curr Opin Rheumatol 18 Suppl 1 S11 S15 10.1097/01.bor.0000229522.89546.7b 16735840 (Pubitemid 44289184)
16. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector, et al. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468 1:CAS:528: DC%2BD2cXos1Snsw%3D%3D 10.1056/NEJMoa022436 14749454 (Pubitemid 38133766)
17. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster, et al. 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441 1:CAS:528:DC%2BD3MXktVSgsbw%3D 10.1056/NEJM200105103441904 11346808 (Pubitemid 32402100)
18. H Dobnig A Sipos Y Jiang A Fahrleitner-Pammer LG Ste-Marie JC Gallagher, et al. 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy J Clin Endocrinol Metab 90 3970 3977 1:CAS:528:DC%2BD2MXmtlCitrg%3D 10.1210/jc.2003-1703 15840739 (Pubitemid 41058159)
19. JP Bilezikian 2008 Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window Curr Osteoporos Rep 6 24 30 10.1007/s11914-008-0005-9 18430397
20. AB Hodsman M Kisiel JD Adachi LJ Fraher PH Watson 2000 Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis Bone 27 311 318 1:CAS:528:DC%2BD3cXltVGqtr0%3D 10.1016/S8756- 3282(00)00316-1 10913928 (Pubitemid 30458828)
21. YL Ma Q Zeng DW Donley LG Ste-Marie JC Gallagher GP Dalsky, et al. 2006 Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis J Bone Miner Res 21 855 864 1:CAS:528:DC%2BD28XlvVamtbg%3D 10.1359/jbmr.060314 16753016 (Pubitemid 43787992)
22. R Lindsay H Zhou F Cosman J Nieves DW Dempster AB Hodsman 2007 Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium J Bone Miner Res 22 495 502 1:CAS:528:DC%2BD2sXpt1Grtrw%3D 10.1359/jbmr.070104 17227219 (Pubitemid 47457425)
23. AD Anastasilakis DG Goulis SA Polyzos S Gerou V Pavlidou G Koukoulis, et al. 2008 Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide Eur J Endocrinol 158 411 415 1:CAS:528: DC%2BD1cXjsFylurg%3D 10.1530/EJE-07-0528 18299476 (Pubitemid 351405007)
24. Y Jiang JJ Zhao BH Mitlak O Wang HK Genant EF Eriksen 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure J Bone Miner Res 18 1932 1941 1:CAS:528: DC%2BD3sXptVyiu74%3D 10.1359/jbmr.2003.18.11.1932 14606504 (Pubitemid 37377441)
25. C Graeff W Timm TN Nickelsen J Farrerons F Marín C Barker EUROFORS High Resolution Computed Tomography Substudy Group, et al. 2007 Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study J Bone Miner Res 22 1426 1433 1:CAS:528:DC%2BD2sXhtVynsLjI 10.1359/jbmr.070603 17547537 (Pubitemid 351339687)
26. RR Recker SP Bare SY Smith A Varela MA Miller SA Morris 2009 Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84 Bone 44 113 119 1:CAS:528:DC%2BD1cXhsFahtLjJ 10.1016/j.bone.2008.09.019 18983947
27. AB Hodsman DC Bauer DW Dempster L Dian DA Hanley ST Harris, et al. 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use Endocr Rev 26 688 703 1:CAS:528:DC%2BD2MXps1Kit7g%3D 10.1210/er.2004-0006 15769903 (Pubitemid 41127277)
28. L Hyldstrup JT Jorgensen G Gaich 2002 Assessment of effects of ly333334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital X-ray radiogrammetry Bone 28 S97
29. J Borggrefe C Graeff TN Nickelsen F Marin CC Glüer 2009 Quantitative computed tomography assessment of the effects of 24 months of teriparatide treatment on 3-D femoral neck bone distribution, geometry and bone strength: results from the EUROFORS study J Bone Miner Res 25 472 481 10.1359/jbmr.090820
30. EP Paschalis EV Glass DW Donley EF Eriksen 2005 Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial J Clin Endocrinol Metab 90 4644 4649 1:CAS:528:DC%2BD2MXnvVWlurc%3D 10.1210/jc.2004-2489 15914535 (Pubitemid 41159354)
31. K Uusi-Rasi LM Semanick JR Zanchetta CE Bogado EF Eriksen M Sato, et al. 2005 Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women Bone 36 948 958 1:CAS:528:DC%2BD2MXltFSlt7Y%3D 10.1016/j.bone.2005.03.003 15878318 (Pubitemid 40797995)
32. JR Zanchetta CE Bogado JL Ferretti O Wang MG Wilson M Sato, et al. 2003 Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis J Bone Miner Res 18 539 543 1:CAS:528:DC%2BD3sXitVyrsb0%3D 10.1359/jbmr.2003.18.3.539 12619939 (Pubitemid 36241071)
33. Y Xiong HJ Yang J Feng ZL Shi LD Wu 2009 Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells J Int Med Res 37 407 416 1:CAS:528:DC%2BD1MXhtFOjt73M 19383235
34. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155. doi: 10.1002/14651858.CD001155.pub2 (Pubitemid 351807494)
35. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1: CD004523. doi: 10.1002/14651858.CD004523.pub3 (Pubitemid 351824594)
36. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley for HORIZON Pivotal Fracture Trial, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528: DC%2BD2sXltVSktLc%3D 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
37. CH Chesnut III A Skag C Christiansen R Recker JA Stakkestad A Hoiseth for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America, Europe (BONE), et al. 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249 1:CAS:528:DC%2BD2cXntFGqurw%3D 10.1359/JBMR.040325 (Pubitemid 41094364)
38. E Seeman 2009 To stop or not to stop, that is the question Osteoporos Int 20 187 195 10.1007/s00198-008-0813-x 19096746
39. R Recker P Masarachia A Santora T Howard P Chavassieux M Arlot, et al. 2005 Trabecular bone microarchitecture after alendronate treatment of osteoporotic women Curr Med Res Opin 21 185 194 1:CAS:528:DC%2BD2MXktFGrsLY%3D 10.1185/030079904X20259 15801989 (Pubitemid 40469895)
40. TE Dufresne PA Chmielewski MD Manhart TD Johnson B Borah 2003 Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography Calcif Tissue Int 73 423 432 1:CAS:528:DC%2BD3sXps1yhsLo%3D 10.1007/s00223-002-2104-4 12964065 (Pubitemid 37466634)
41. E Durchschlag EP Paschalis R Zoehrer P Roschger P Fratzl R Recker, et al. 2006 Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate J Bone Miner Res 21 1581 1590 1:CAS:528:DC%2BD28XhtFekt7zI 10.1359/jbmr.060701 16995813 (Pubitemid 44484603)
42. B Borah TE Dufresne PA Chmielewski TD Johnson A Chines MD Manhart 2004 Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography Bone 34 736 746 1:CAS:528:DC%2BD2cXisF2ntbo%3D 10.1016/j.bone.2003.12.013 15050906 (Pubitemid 38393811)
43. P Roschger S Rinnerthaler J Yates GA Rodan P Fratzl K Klaushofer 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women Bone 29 185 191 1:CAS:528:DC%2BD3MXlvFWkurk%3D 10.1016/S8756-3282(01)00485-9 11502482 (Pubitemid 32737191)
44. RR Recker PD Delmas J Halse IR Reid S Boonen PA García-Hernandez, et al. 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure J Bone Miner Res 23 6 16 1:CAS:528: DC%2BD1cXhtVCmt7c%3D 10.1359/jbmr.070906 17892374
45. GY Boivin PM Chavassieux AC Santora J Yates PJ Meunier 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women Bone 27 687 694 1:CAS:528:DC%2BD3cXosFygtL8%3D 10.1016/S8756-3282(00)00376-8 11062357
46. B Borah EL Ritman TE Dufresne SM Jorgensen S Liu J Sacha, et al. 2005 The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover Bone 37 1 9 1:CAS:528:DC%2BD2MXlsFCqs70%3D 10.1016/j.bone.2005.03. 017 15894527 (Pubitemid 40848411)
47. B Borah TE Dufresne EL Ritman SM Jorgensen S Liu PA Chmielewski, et al. 2006 Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography Bone 39 345 352 1:CAS:528:DC%2BD28Xls1ejtLo%3D 10.1016/j.bone.2006.01.161 16571382 (Pubitemid 43851366)
48. PM Chavassieux ME Arlot C Reda L Wei AJ Yates PJ Meunier 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis J Clin Invest 100 1475 1480 1:CAS:528:DyaK2sXmt1Cqsb8%3D 10.1172/JCI119668 9294113
49. EF Eriksen F Melsen E Sod I Barton A Chines 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis Bone 3 620 625 10.1016/S8756-3282(02)00869-4 (Pubitemid 35449706)
50. R Zoehrer P Roschger EP Paschalis JG Hofstaetter E Durchschlag P Fratzl, et al. 2006 Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women J Bone Miner Res 21 1106 1112 1:CAS:528: DC%2BD28XntlWqu7s%3D 10.1359/jbmr.060401 16813531 (Pubitemid 43962839)
51. P Roschger A Lombardi BM Misof G Maier N Fratzl-Zelman P Fratzl, et al. 2010 Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the Fracture Intervention Trial Long-Term Extension (FLEX) J Bone Miner Res 25 48 55 1:CAS:528:DC%2BC3cXksl2lu7Y%3D 10.1359/jbmr.090702 19580465
52. RR Recker RS Weinstein CH Chesnut III RC Schimmer P Mahoney C Hughes, et al. 2004 Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study Osteoporos Int 15 231 237 1:CAS:528:DC%2BD2cXhsl2hsLg%3D 10.1007/s00198-003- 1530-0 14727011 (Pubitemid 38391539)
53. M McClung R Recker P Miller D Fiske J Minkoff A Kriegman, et al. 2007 Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate Bone 41 122 128 1:CAS:528:DC%2BD2sXmsFKkurc%3D 10.1016/j.bone.2007.03.011 17468062 (Pubitemid 46901056)
54. AL Boskey L Spevak RS Weinstein 2009 Spectroscopic markers of bone quality in alendronate-treated postmenopausal women Osteoporos Int 20 793 800 1:CAS:528:DC%2BD1MXjvFaqtrs%3D 10.1007/s00198-008-0725-9 18769963
55. K Iba J Takada N Hatakeyama Y Ozasa T Wada T Yamashita 2008 Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment J Orthop Sci 13 438 441 1:CAS:528:DC%2BD1cXht1artbzK 10.1007/s00776-008-1265-z 18843458
56. RD Chapurlat M Arlot B Burt-Pichat P Chavassieux JP Roux N Portero-Muzy, et al. 2007 Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study J Bone Miner Res 22 1502 1509 1:CAS:528:DC%2BD2sXhtFyhu7nJ 10.1359/jbmr.070609 17824840 (Pubitemid 351229320)
57. RD Chapurlat PD Delmas 2009 Bone microdamage: a clinical perspective Osteoporos Int 20 1299 1308 1:STN:280:DC%2BD1MvnsVKgug%3D%3D 10.1007/s00198-009-0899-9 19291343
58. DM Black MP Kelly HK Genant L Palermo R Eastell C Bucci-Rechtweg the Fracture Intervention Trial and HORIZON Pivotal Fracture Trial Steering Committees, et al. 2010 Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N Engl J Med 362 1761 1771 1:CAS:528:DC%2BC3cXmtVSrsr4%3D 10.1056/NEJMoa1001086 20335571
59. E Shane 2010 Evolving data about subtrochanteric fractures and bisphosphonates N Engl J Med 362 1825 1827 1:CAS:528:DC%2BC3cXmtVKgtb0%3D 10.1056/NEJMe1003064 20335574
60. M Arlot PJ Meunier G Boivin L Haddock J Tamayo R Correa-Rotter, et al. 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters J Bone Miner Res 20 1244 1253 1:CAS:528:DC%2BD2MXmsFyitLw%3D 10.1359/JBMR.050309 15940379 (Pubitemid 40863814)
61. TM Keaveny DW Donley PF Hoffmann BH Mitlak EV Glass JA San Martin 2007 Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis J Bone Miner Res 22 149 157 1:CAS:528:DC%2BD2sXhtVWnurk%3D 10.1359/jbmr.061011 17042738 (Pubitemid 46032608)
62. Fonseca JE (2008) Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength. Rheumatology (Oxford) 47(Suppl 4):iv17-iv19
63. AD Anastasilakis DG Goulis SA Polyzos S Gerou I Ballaouri Z Efstathiadou, et al. 2009 No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial Clin Endocrinol (Oxf) 70 522 526 1:CAS:528:DC%2BD1MXkt12gt74%3D 10.1111/j.1365-2265.2008.03342.x
64. AD Anastasilakis SA Polyzos A Avramidis A Papatheodorou E Terpos 2009 Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide Horm Metab Res 41 559 562 1:CAS:528:DC%2BD1MXhtVCgs7vF 10.1055/s-0029-1192035 19204890
65. O'Donnell S, Cranney A, Wells GA, Adachi J, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 4:CD005326. doi: 10.1002/14651858.CD005326.pub3
66. JY Reginster E Seeman MC De Vernejoul S Adami J Compston C Phenekos, et al. 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 2822 1:CAS:528: DC%2BD2MXkt1Wgt78%3D 10.1210/jc.2004-1774 15728210 (Pubitemid 40686329)
67. ME Arlot Y Jiang HK Genant J Zhao B Burt-Pichat JP Roux, et al. 2008 Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate J Bone Miner Res 23 215 222 1:CAS:528:DC%2BD1cXhvVOhtr8%3D 10.1359/jbmr.071012 17922612 (Pubitemid 351160035)
68. P Roschger I Manjubala N Zoeger F Meirer R Simon, et al. 2010 Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment J Bone Miner Res 25 891 900 10.1359/jbmr.090702 20437609
69. G Boivin D Farlay MT Khebbab X Jaurand PD Delmas PJ Meunier 2010 In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization Osteoporos Int 21 667 677 1:CAS:528:DC%2BC3cXivVGqtLc%3D 10.1007/s00198-009-1005-z 19597910
70. LB Tankó 2007 Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe? Curr Opin Investig Drugs 8 830 835 17907059
71. SR Cummings J San Martin MR McClung ES Siris R Eastell IR Reid FREEDOM Trial, et al. 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF 10.1056/NEJMoa0809493 19671655
72. TJ Beck EM Lewiecki PD Miller D Felsenberg Y Liu B Ding 2008 Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate J Clin Densitom 11 351 359 10.1016/j.jocd.2008.04. 001 18495508
73. DL Kendler C Roux CL Benhamou JP Brown M Lillestol S Siddhanti, et al. 2009 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy J Bone Miner Res 25 72 81 10.1359/jbmr.090716
74. PD Delmas AA Licata JY Reginster GG Crans P Chen DA Misurski, et al. 2006 Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover Bone 39 237 243 1:CAS:528:DC%2BD28Xls1ejt70%3D 10.1016/j.bone.2006.02.003 16563890 (Pubitemid 43851376)
75. S Boonen F Marin B Obermayer-Pietsch ME Simoes C Barker EV Glass, et al. 2008 Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis J Clin Endocrinol Metab 93 852 860 1:CAS:528:DC%2BD1cXjsFynurg%3D 10.1210/jc.2007-0711 18160462 (Pubitemid 351398563)
76. PD Miller PD Delmas R Lindsay NB Watts M Luckey J Adachi, et al. 2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate J Clin Endocrinol Metab 93 3785 3793 1:CAS:528:DC%2BD1cXht1Gmur%2FN 10.1210/jc.2008-0353 18682511
77. ET Middleton SA Steel SM Doherty 2007 The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice Calcif Tissue Int 81 335 340 1:CAS:528:DC%2BD2sXht1Oks77J 10.1007/s00223-007-9066-5 17938845 (Pubitemid 350077202)
78. BM Obermayer-Pietsch F Marin EV McCloskey P Hadji J Farrerons S Boonen EUROFORS Investigators, et al. 2008 Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment J Bone Miner Res 10 1591 1600 10.1359/jbmr.080506
79. B Jobke M Pfeifer HW Minne 2009 Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest Connect Tissue Res 50 46 54 1:CAS:528:DC%2BD1MXhvVSkt7o%3D 10.1080/03008200802412462 19212852
80. H Dobnig JJ Stepan DB Burr J Li D Michalska A Sipos, et al. 2009 Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate J Bone Miner Res 24 1998 2006 1:CAS:528:DC%2BC3cXht1Wnsrc%3D 10.1359/jbmr.090527 19453263
81. BZ Leder RM Neer JJ Wyland HW Lee SA Burnett-Bowie JS Finkelstein 2009 Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis J Clin Endocrinol Metab 94 2915 2921 1:CAS:528:DC%2BD1MXpvFGntLg%3D 10.1210/jc.2008-2630 19435827
82. JS Finkelstein JJ Wyland BZ Leder SM Burnett-Bowie H Lee H Jüppner, et al. 2009 Effects of teriparatide retreatment in osteoporotic men and women J Clin Endocrinol Metab 94 2495 2501 1:CAS:528:DC%2BD1MXosl2ks7Y%3D 10.1210/jc.2009-0154 19401368
83. RS Rittmaster M Bolognese MP Ettinger DA Hanley AB Hodsman DL Kendler, et al. 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate J Clin Endocrinol Metab 85 2129 2134 1:CAS:528:DC%2BD3cXlsVequr0%3D 10.1210/jc.85.6.2129 10852440 (Pubitemid 32269232)
84. DM Black SL Greenspan KE Ensrud L Palermo JA McGowan TF Lang PaTH Study Investigators, et al. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 1207 1215 1:CAS:528:DC%2BD3sXns1Kmsrw%3D 10.1056/NEJMoa031975 14500804 (Pubitemid 37152030)
85. DM Black JP Bilezikian KE Ensrud SL Greenspan L Palermo T Hue, et al. 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 555 565 1:CAS:528:DC%2BD2MXnsVWmtb0%3D 10.1056/NEJMoa050336 16093464 (Pubitemid 41138937)
86. TM Keaveny PF Hoffmann M Singh L Palermo JP Bilezikian SL Greenspan, et al. 2008 Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans J Bone Miner Res 23 1974 1982 1:CAS:528:DC%2BD1MXosVyltr8%3D 10.1359/jbmr.080805 18684084